Upgrade to SI Premium - Free Trial

Alnylam Pharmaceuticals (ALNY) Reiterated at Buy by Stifel Post CARDIO-TTRansform Failure

July 14, 2026 7:29 AM
Stifel analyst Paul Matteis reiterated a Buy rating and $444.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented, "ALNY ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments